First Tracks Biotherapeutics — Third Quarter 2026 Earnings Summary

First Tracks Biotherapeutics reported that its lead candidate ANB033 achieved statistically significant protection against gluten-induced intestinal damage and symptoms in a Phase 1b celiac disease trial cohort. The company has completed enrollment for a second celiac disease cohort with top-line data expected in the first quarter of 2027 and plans to initiate late-stage trials in 2027. Additionally, enrollment is ongoing for an ANB033 trial in eosinophilic esophagitis, with results anticipated in the third quarter of 2027, while Phase 2 development in vitiligo is scheduled for the first half of 2027. Financially, the company reported a net loss of $31.4 million for the third quarter of 2026 and holds $155.6 million in cash, with pro forma cash reaching $343 million following a $200 million private placement.